



Changes in the plasma proteome at asymptomatic and symptomatic 
stages of autosomal dominant Alzheimer’s disease 
 
Julia Muenchhoff1, Anne Poljak1,2,3, Anbupalam Thalamuthu1, Veer B. Gupta4,5, Pratishtha 
Chatterjee4,5,6, Mark Raftery2, Colin L. Masters7, John C. Morris8,9,10, Randall J. Bateman8,9, Anne M. 




Supplementary Figure S1. Ratios of proteins differentially abundant in asymptomatic carriers of 
PSEN1 and APP Dutch mutations. Mean ratios and standard deviations of plasma proteins from 
asymptomatic PSEN1 mutation carriers (PSEN1) and APP Dutch mutation carriers (APP) relative to 
reference masterpool as quantified by iTRAQ. Ratios that significantly differed are marked with 
asterisks (* p < 0.05; ** p < 0.01). C4A, complement C4-A; AZGP1, zinc-α-2-glycoprotein; HPX, 
hemopexin; PGLYPR2, N-acetylmuramoyl-L-alanine amidase isoform 2; α2AP, α-2-antiplasmin; 
APOL1, apolipoprotein L1; C1 inhibitor, plasma protease C1 inhibitor; ITIH2, inter-α-trypsin 




Supplementary Figure S2. Venn diagrams visualising the overlap of proteomic changes between four studies. The diagrams visualise the overlap of 
individual proteins (A) and protein families (B) differentially abundant in plasma from ADAD mutation carriers (this study), in CSF from ADAD mutation 
carriers (Ringman et al., 2012, Arch Neurol 69, 96-104) and in plasma from MCI and LOAD subjects (Song et al., 2012, Proteome Sci 12, 5; Muenchhoff et 
al., 2015, J Alzheimers Dis 43, 1355-1373). A) Arrows indicate increased or decreased levels. For abbreviations see Table 2. B) Accession numbers for the 
PANTHER protein family database are displayed without the PTHR prefix. Full accession numbers and protein family names are: PTHR10083, kunitz-type 
protease inhibitor-related; PTHR10127, discoidin, cub, egf, laminin , and zinc metalloprotease domain containing; PTHR10338, von willebrand factor, type 
a domain containing; PTHR10395, uricase and transthyretin-related; PTHR10574, netrin/laminin-related; PTHR10612, apolipoprotein D; PTHR10970, 
clusterin; PTHR11027, apolipoprotein A-II;PTHR11385, serum albumin-related; PTHR11412, macroglobulin / complement; PTHR11461, serine protease 
inhibitor, serpin; PTHR11738, MHC class I NK cell receptor; PTHR11967, α-1-acid glycoprotein; PTHR11977, villin; PTHR13769, apolipoprotein B; 
PTHR13814, fetuin; PTHR16565, apolipoprotein C-I; PTHR16566, apolipoprotein C-II; PTHR18976, apolipoprotein; PTHR19143, 
fibrinogen/tenascin/angiopoeitin; PTHR19325, complement component-related sushi domain-containing; PTHR23266, immunoglobulin heavy chain; 























































































Supplementary Figure S3. Immunodepletion of plasma samples. A) Chromatograms for 
fractionation of plasma (20 µl) from 35 participants into low and high abundance proteins using the 
Multiple Affinity Removal System Hu6 column and buffer kit by Agilent (Santa Clara, USA) on a HP 
1090 HPLC system (Agilent, Santa Clara, USA). B) Colloidal coomassie-stained sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (NuPAGE 4-12% Bis-Tris, Life Technologies, Carlsbad, 
CA, USA) of unfractionated plasma proteins (50 µg, lanes 1-4), high abundance plasma proteins (45 
µg, lanes 4-8) and low abundance plasma proteins (5 µg, lanes 9-12) from four DIAN participants (one 
non-carrier, two asymptomatic mutation carriers and one symptomatic mutation carrier who were 
randomly chosen from each group). The Hu6 column removes the six most abundant proteins 
equivalent to 85-90% of total plasma protein. Hence, proteins were loaded equivalent to 100% for 
unfractionated plasma proteins, 90% for the high abundance protein fraction and 10% for the low 
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Supplementary Figure S4. Colloidal coomassie-stained sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS PAGE). SDS PAGE (NuPAGE 4-12% Bis-Tris, Life Technologies, 
Carlsbad, CA, USA) of low abundance plasma proteins (10 µg) of 35 DIAN participants and non-
carrier (NC) masterpool. Samples for iTRAQ multiplex runs 1 and 2 (A), 3 (B), 4 (C), 5 (D) and 6 (E). 
The lane corresponding to the NC masterpool in each iTRAQ is labeled with an asterisk. The different 

























Supplementary Table S1. Protein summary results for ProteinPilot v4.0 analysis of all iTRAQ 
multiplex experiments. Numbers for proteins detected refer to all proteins identified at 1% FDR or 
95% confidence. Hence, this includes contaminating proteins (e.g. porcine trypsin), proteins with no 
quantification data or only one distinct peptide for identification. In contrast, Supplementary Table S2 
lists proteins used in statistical analyses, which all have quantification data and a minimum of two 













1 105 103 220 5607 18117 23.9 
2 109 100 202 5865 21722 29.1 
3 115 112 251 6202 23566 31.5 
4 97 103 235 5940 21475 28.7 
5 102 98 508 5581 20137 26.8 
6 125 125 297 6367 22791 30.4 
a1% FDR 




Supplementary Table S3. Proteins that differed significantly in abundance between asymptomatic carriers of PSEN1 mutations and noncarriers 
or APP Dutch mutation carriers and noncarriers. A linear model including age, gender, APOE ε4 status, estimated years from expected symptom 
onset (EYO) and mutation type/status (i.e. noncarrier, PSEN1 and APP groupings) as covariates was used (see Materials and Methods section in the main 
text for details on the statistical analysis). Proteins with a q value of < 0.05 are considered significant and marked with an asterisk. Proteins marked in 
bold also differed significantly in abundance in NC, aMC and sMC group comparisons. 
   NC vs PSEN1 NC vs APP 









Collagen fibril organisation Lumican (P51884) LUM 1.52 0.31 1.22×10-5* 0.57 0.34 0.2565 
Lipid metabolism Apolipoprotein L1 (O14791) APOL1 -1.23 0.45 0.0216* 0.49 0.38 0.3785 
Heme transport Hemopexin (P02790) HPX 0.93 0.37 0.0338* -0.11 0.11 0.4456 
Thyroid hormone transport Thyroxine-binding globulin (P05543) SERPINA7 0.61 0.25 0.0371* 0.57 0.38 0.3105 
Vascular function Plasma kallikrein (P03952) KLKB1 0.97 0.20 1.22×10-5* 0.64 0.70 0.4456 
Blood coagulation, vascular 
function Kininogen-1 (P01042) KNG1 0.75 0.32 0.0371* 0.18 0.35 0.5357 
Acute phase, cell chemotaxis Serum amyloid A-4 protein (P35542) SAA4 -1.02 0.21 1.22×10-5* -0.29 0.25 0.4095 
Innate immune response Isoform 2 of N-acetylmuramoyl-L-alanine amidase (Q96PD5-2) PGLYRP2 0.87 0.21 0.0002* -0.25 0.32 0.4456 
Immune response Ig γ-3 chain C region (P01860) IGHG3 0.92 0.38 0.0368* 0.33 0.42 0.4456 
Complement system Plasma protease C1 inhibitor (P05155) SERPING1 1.57 0.34 3.34×10-5* 0.05 0.26 0.5873 
Complement system Complement C4-B (P0C0L5) C4B 1.08 0.36 0.0127* 0.00 0.22 0.6228 
Complement system Complement C4-A (P0C0L4) C4A 1.63 0.58 0.0167* 0.08 0.12 0.4880 
Complement system Complement factor H (P08603) CFH 0.56 0.24 0.0371* 0.47 0.26 0.2181 
Complement system Complement C3 (P01024) C3 1.53 0.53 0.0162* 0.83 0.30 0.0223* 
Acute phase, angiogenesis, 
cell adhesion, cell shape Fibronectin (P02751) FN1 1.30 0.44 0.0156* 0.94 0.37 0.0400* 
Acute phase, fibrinolysis, 
platelet activation α-2-antiplasmin (P08697) SERPINF2 1.29 0.54 0.0371* -0.29 0.09 0.0065* 
Vascular function Kallistatin (P29622) SERPINA4 0.30 0.45 0.2995 -0.25 0.10 0.0439* 
Hemostasis Heparin cofactor 2 (P05546) SERPIND1 0.85 0.73 0.2250 0.44 0.06 9.58×10-11* 
Complement system C4b-binding protein beta chain (P20851) C4BPB 0.04 0.25 0.3561 0.31 0.09 0.0030* 
Complement system Complement factor I (P05156) CFI -0.30 0.61 0.3204 0.55 0.16 0.0041* 
Complement system Complement C1r subcomponent (P00736) C1R -0.14 0.35 0.3204 -0.60 0.21 0.0223* 
Complement system Complement component C6 (P13671) C6 -0.35 0.38 0.2421 -0.65 0.09 5.73×10-12* 
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   NC vs PSEN1 NC vs APP 









Immune response Zinc-α-2-glycoprotein (P25311) AZGP1 0.27 0.19 0.2003 -0.76 0.10 2.91×10-12* 
Inflammatory response Attractin (O75882) ATRN -0.74 0.53 0.2003 -0.98 0.22 6.25×10-5* 
Retinol transport Retinol-binding protein 4 (P02753) RBP4 -0.17 0.43 0.3204 -0.73 0.06 <1.00×10-13* 
Vitamin E transport Afamin (P43652) AFM 0.40 0.71 0.3204 0.84 0.09 <1.00×10-13* 
Positive regulation of 
neurogenesis 
Pigment epithelium-derived factor 





Supplementary Table S4. β coefficients, standard errors and p-values for associations of proteins with glucose metabolism in the precuneus 
(FDG PET precuneus) and/or caudate nucleus (FDG PET caudate nucleus). A linear model including age, gender, APOE ε4 status, estimated years 
from expected symptom onset (EYO) and mutation status as covariates was used (see Materials and Methods section in the main text for details on the 
statistical analysis). 
    FDG PET caudate nucleus FDG PET precuneus 









α-1B-glycoprotein (P04217) A1BG 2.12 0.34 2.55×10-10* 1.07 0.43 0.0128 
Apolipoprotein E  (P02649) APOE 0.06 0.45 0.8948 0.35 0.09 3.78×10-5* 
Apolipoprotein M  (O95445) APOM 0.39 0.97 0.6892 1.85 0.26 1.88×10-12* 
Attractin  (O75882) ATRN 7.30 1.60 5.19×10-6* -0.20 1.14 0.8628 
Complement component C4-A  (P0C0L4) C4A 1.15 0.34 0.0007 0.99 0.24 4.53×10-5* 
Complement component C6  (P13671) C6 2.13 0.48 8.85×10-6* 0.50 0.50 0.3177 
Fibronectin  (P02751) FN1 0.27 0.57 0.6394 0.74 0.17 1.27×10-5* 
Hemoglobin subunit β  (P68871) HBB 0.61 0.05 <1.00×10-14* 0.06 0.05 0.2180 
Histidine-rich glycoprotein  (P04196) HRG 2.09 0.36 7.25×10-9* 0.56 0.41 0.1778 
Ig γ-3 chain C region  (P01860) IGHG3 -1.59 0.36 7.86×10-9* -0.33 0.24 0.1651 
Ig µ chain C region  (P01871) IGHM -1.69 0.36 2.02×10-6* -0.29 0.36 0.4276 
Kininogen-1  (P01042) KNG1 -0.71 0.31 0.0233 0.20 0.12 0.1064 
Isoform LMW of Kininogen-1  (P01042-2) KNG1 0.89 0.31 1.98×10-6* 0.20 0.12 0.0245 
Lumican  (P51884) LUM -5.92 1.64 2.98×10-4* -0.85 0.51 0.0971 
Pigment epithelium-derived factor  (P36955) SERPINF1 4.63 1.14 4.98×10-5* 0.66 1.30 0.6129 
Plasma kallikrein  (P03952) KLKB1 -2.52 0.32 6.00×10-15* 0.11 0.58 0.8467 
Plasma protease C1 inhibitor  (P05155) SERPING1 -0.95 0.56 0.0876 0.67 0.16 2.26×10-5* 
Thyroxine-binding globulin  (P05543) SERPINA7 0.81 0.37 0.0268 -1.20 0.34 4.56×10-4* 




Supplementary Table S5. β coefficients, standard errors and p-values for associations of proteins with amyloid deposition in the precuneus (PiB 
PET precuneus) and/or caudate nucleus (PiB PET caudate nucleus). A linear model including age, gender, APOE ε4 status, estimated years from 
expected symptom onset (EYO) and mutation status as covariates was used (see Materials and Methods section in the main text for details on the 
statistical analysis). 
    PiB PET caudate nucleus PiB PET precuneus 









Complement component C4-A  (P0C0L4) C4A -1.46 0.20 1.48×10-13* -1.32 0.19 7.84×10-12* 
Complement component C8 β chain  (P07358) C8B 0.21 0.06 4.39×10-4* 0.26 0.09 0.0033 
Complement factor I  (P05156) CFI -1.35 0.47 0.0040 -1.28 0.30 1.88×10-5* 
Fibrinogen β chain  (P02675) FGB -0.25 0.07 5.94×10-4* -0.22 0.11 0.0522 
Heparin cofactor 2  (P05546) SERPIND1 -1.28 0.33 8.98×10-5* -0.96 0.50 0.0564 
Kininogen-1  (P01042) KNG1 -0.72 0.15 2.12×10-6* -0.61 0.13 4.83×10-16* 
Plasma kallikrein  (P03952) KLKB1 -1.71 0.46 2.18×10-4* -1.50 0.69 0.0301 
Tetranectin  (P05452) CLEC3B 0.82 0.21 1.05×10-4* 0.83 0.19 1.81×10-5* 
Thyroxine-binding globulin  (P05543) SERPINA7 0.68 0.33 0.0385 0.83 0.22 1.19×10-4* 
Vitamin K-dependent protein S  (P07225) PROS1 -3.48 0.45 1.28×10-14* -3.67 0.48 2.21×10-14* 
Zinc-α-2-glycoprotein  (P25311) AZGP1 0.52 0.18 0.0031 0.61 0.17 4.35×10-4* 
*Association is significant at Bonferroni corrected p < 0.05/81. 
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Supplementary Table S6. β coefficients, standard errors and p-values for associations of proteins with average precuneus thickness. A linear 
model including age, gender, APOE ε4 status, estimated years from expected symptom onset (EYO) and mutation status as covariates was used (see 
Materials and Methods section in the main text for details on the statistical analysis). 
    Average precuneus thickness 
Protein (UniProt accession) Gene symbol β coefficient Standard Error p-value 
α-2-antiplasmin  (P08697) SERPINF2 2.41 0.63 1.21×10-4* 
Apolipoprotein A-I  (P02647) APOA1 1.48 0.42 4.24×10-4* 
Complement C1r subcomponent  (P00736) C1R -1.68 0.30 1.38×10-8* 
Complement component C4-A  (P0C0L4) C4A 1.07 0.30 4.06×10-4* 
Complement factor B  (P00751) CFB -0.68 0.20 5.05×10-4* 
Fibronectin  (P02751) FN1 0.85 0.16 1.41×10-4* 
*Association is significant at Bonferroni corrected p < 0.05/81. 
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Supplementary Table S7. β coefficients, standard errors and p-values for associations of proteins with MMSE score and/or episodic memory 
represented by LM-IA and LM-IIA scores. A linear model including age, gender, APOE ε4 status, estimated years from expected symptom onset 
(EYO) and mutation status as covariates was used (see Materials and Methods section in the main text for details on the statistical analysis). 
















d Error p-value 
Complement component 
C4-A  (P0C0L4) C4A 1.08 0.13 <1.00×10-14* 1.30 0.39 0.0008 1.27 0.32 6.15×10-5* 
Hemoglobin subunit β  
(P68871) HBB 0.61 0.08 1.82×10-13* 0.43 0.18 0.0144 0.68 0.11 1.44×10-9* 
Lumican  (P51884) LUM -2.86 0.54 1.47×10-7* -1.08 0.74 0.1445 -0.77 0.78 0.3287 
Coagulation factor XII 
(P00748) F12 0.65 0.15 1.80×10-5* 0.75 0.26 0.0040 0.76 0.25 0.0021 
α-2-HS-glycoprotein 
(P02765) AHSG -0.68 0.20 0.0008 -0.93 0.28 0.0010 -0.82 0.21 6.59×10-5* 
Vitronectin (P04004) VTN -1.03 0.46 0.0245 -1.39 0.54 0.0106 -1.47 0.39 1.91×10-4* 
Complement component 
C2 (P06681) C2 -1.21 0.21 1.82×10-8* -0.83 0.92 0.3634 -0.84 0.94 0.3683 
C4b-binding protein β 
chain (P20851) C4BPB -0.44 1.25 0.7228 3.54 0.84 2.69×10-5* 3.82 0.70 5.03×10-8* 
Kallistatin (P29622) SERPINA4 -1.18 0.27 1.22×10-5* -0.93 0.50 0.0642 -0.65 0.45 0.1460 
*Association is significant at Bonferroni corrected p < 0.05/81. 
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Supplementary Table S8. Plasma levels of heparin cofactor II (HCII) for non-carriers (NC), asymptomatic (aMC) and symptomatic mutation 
carriers (sMC). HCII was quantified using ELISA in the low abundance protein fractions derived from plasma and used in iTRAQ experiments. Protein 
levels are expressed as µg protein of interest per mg total protein in the sample. 
 HCII 
NC (n = 12), µg per mg protein (SD) 16.73  (3.31) 
aMC (n = 15), µg per mg protein (SD) 17.35  (3.99) 
sMC (n = 2), µg per mg protein (SD) 16.42  (3.47) 





Plasma immunodepletion and sample preparation 
The six most abundant plasma proteins (albumin, transferrin, immunoglobulins G and A, haptoglobin 
and antitrypsin) were immunodepleted from plasma samples (20 µl) using the Agilent (Santa Clara, 
USA) Multiple Affinity Removal System Hu6 column and buffer kit on a HP 1090 HPLC system 
(Agilent, Santa Clara, USA) according to manufacturer’s instructions. We previously verified that this 
method only removes the six targeted proteins 1. The depleted fractions were buffer exchanged and 
concentrated into 20 mM NaHCO3 using Amicon 3 kDa centrifugal devices (Millipore, Billerica, 
USA). Total protein was quantified by absorbance measurements (280 nm) with a ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, USA), using the relationship; A280 of 1 = 1 
mg mL-1. Low abundance protein fractions were analyzed by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS PAGE) (NuPAGE 4-12% gradient Bis-Tris gels, Life Technologies, 
Carlsbad, USA) to verify consistent depletion of the six most abundant proteins across all samples 
(Supplementary Fig. S3 and S4). Samples were stored at -80 °C until further use. 
 
iTRAQ-labelling and purification of labelled peptides 
Labelling of tryptic peptides with iTRAQ 8-plex reagents (Sciex, Framingham, USA) was carried out 
according to manufacturer’s instructions with slight modifications as outlined in Muenchhoff, et al. 1. 
Briefly, 50 µg of the low abundance proteins from each plasma sample were reduced with tris (2-
carboxyethyl) phosphine, alkylated with iodoacetamide and digested with trypsin overnight at 37°C. 
Tryptic peptides were combined with iTRAQ reagents and the pH-adjusted labelling reaction was 
allowed to proceed for 2 hrs at room temperature. iTRAQ-labelled peptides were combined and passed 
through a cation exchange cartridge to remove excess reagents. The eluent was evaporated to dryness, 
resuspended in 500 µl 0.2% heptafluorobutyric acid (HFBA) and purified using a C18 macrotrap 
(Michrom Bioresources, Auburn, USA). To ensure maximal recovery of labelled peptides, the C18 
flow through was passed through an Oasis cartridge to capture any peptides not bound on the 
macrotrap. The eluents from both cartridges were combined, evaporated to dryness and resuspended in 
100 µl 0.05% HFBA, 1% formic acid for liquid chromatography tandem mass spectrometry (LC-
MSMS) analysis.  
 
LC-MSMS 
iTRAQ-labelled peptides were analysed by LC-MSMS. LC was carried out on a LC Packings capillary 
HPLC system, comprised of a Dionex UltiMate 3000 RSLCnano pump system, Switchos valve unit 
and Famos autosampler (Thermo Scientific Dionex, Waltham, USA). The resuspended iTRAQ 
labelled peptides were injected onto a C18 precolumn cartridge (Acclaim PepMap 100, 5 µm 100 Å, 
Thermo Scientific Dionex, Waltham, USA), which was washed for 10 min prior to switching inline to 
a capillary column (10 cm) containing C18 reverse phase packing material (Reprosil-Pur, 1.9 µ, 200 Å, 
Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). Peptides were eluted using a 240 min gradient 
of buffer A (H2O:CH3CN of 98:2 containing 0.1% formic acid) to buffer B (H2O:CH3CN of 20:80 
containing 0.1% formic acid) at 200 nL/min. High voltage (2300 V) was applied through a low volume 
tee (Upchurch Scientific, Oak Harbor, USA) at the column inlet and the outlet positioned ~1 cm from 
the orifice of a TripleTOF 5600+ hybrid tandem mass spectrometer (ABSciex, Foster City, USA). 
Positive ions were generated by electrospray ionization and the TripleTOF 5600+ system operated in 
information-dependent acquisition mode. A time of flight MS survey scan was acquired (m/z 375-
1600, 0.4 s) and up to ten multiply charged ions (m/z 375-1250, counts > 200, charge state ≥ 2+ and ≤ 
5+) sequentially selected by Q1 for MSMS analysis. Nitrogen was used as collision gas and an 
optimum collision energy automatically chosen (based on charge state and mass). Tandem mass 





Proteins in inflammation 
Four components of the complement system were found differentially abundant in NC, aMC and sMC, 
namely, C3, C5, C6 and C4b-binding protein α chain. There is evidence to indicate that the 
complement system might play a crucial role in AD pathology. Aβ interacts with components of the 
classical and alternate pathway, activating both in the AD brain 2,3. Activation of the complement 
system in AD affords some protection in the form of clearance of Aβ, but also causes harm through 
chronic inflammation leading to tissue damage and lysis of neurons 3. Many studies have previously 
suggested complement components as biomarkers for AD (e.g. 1,4-7). 
 
ACT, one of three serine protease inhibitors (SERPIN) found differentially abundant, is an acute phase 
protein, regulating protease activity of neutrophil cathepsin G, mast cell chymase and others during 
inflammation, thereby preventing tissue damage 8. It might also be involved in atherosclerotic 
processes and stabilisation of the aorta as indicated by its differential vascular expression in 
atherosclerotic lesions and abdominal aortic aneurysms 9. Its expression is elevated in the AD brain, it 
co-localises with amyloid plaques and might induce tau hyperphosphorylation 10,11. In vivo studies in 
transgenic mouse models report accelerated amyloid plaque formation upon expression of human ACT 
10,12-16, which could potentially be due to ACT inhibiting a serine protease involved in Aβ degradation 
17. Although controversial, variation in the SERPINA3 promoter and ACT protein sequence have also 
been associated with increased risk of LOAD 18-20. A number of reports suggested ACT levels in 
plasma/serum as a biomarker for LOAD (see 21 for a review). 
 
AHSG also known as fetuin-A is a multifunctional negative acute phase protein that can bind cations, 
such as calcium. It is involved in regulation of mineralization and ostoegenesis, insulin signaling as 
well as inflammation 22. AHSG serum/plasma levels are known to predict incident type 2 diabetes and 
vascular disease risk due to its inhibitory action on vascular calcification 23. In a rodent model, 
peripherally administered bovine AHSG protected against early cerebral ischemic injury, likely due to 
its anti-inflammatory properties 24. Due to its links to vascular disease and neuroinflammation, both 
components of AD pathology, AHSG has been proposed as a biomarker for LOAD in plasma and 
CSF, and was shown to associate with severity of cognitive decline 23,25-27. Individuals homozygous 
for the AHSG 1 allele in an Italian population were found to be at nearly four times greater risk of 
developing LOAD 28. 
 
Protein α-1-microglobulin/bikunin precursor is the precursor for the structurally and functionally 
unrelated proteins α-1-microglobulin and bikunin. α-1-microglobulin is a member of the lipocalin 
superfamily, a group of proteins that carry lipophilic ligands. It may protect cells from oxidative stress 
by transporting heme groups and free radicals released from hemoglobin from cytosols and 
extravascular fluids to the kidneys 29. It also negatively regulates the immune response of 
lymphocytes, T-cells and granulocytes 30-32. α-1-microglobulin levels were found to differ in the 
plasma from AD and control patients 33 and associated with brain atrophy in AD patients 34. Bikunin, 
also known as inter-α-trypsin inhibitor light chain, is a Kunitz-type protease inhibitor possibly 
involved in endothelial cell growth and extracellular matrix stabilisation 35,36. Proteins in the inter-α-
trypsin inhibitor family consist of the common light chain protein bikunin linked to one or two of 
various heavy chains (H1-4) by a chondroitin sulphate chain. Interestingly, significant differences in 
ITIH2 were also observed here. The protease inhibitory activity of bikunin might prevent 
inflammation-related proteolytic activity. The inter-α-trypsin inhibitor heavy chains can be transferred 
to hyaluronan (a major component of the pericellular matrix), resulting in formation of a heavy chain-
hyaluronan complex and the release of bikunin, which is then excreted into urine. Heavy chains also 
interact with components of the complement system to lower levels of the powerful mediator C5a 37. 
Changes in abundance of plasma inter-α-trypsin inhibitor heavy chain 2 were previously reported in 
MCI 1 and LOAD 21,38.  
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ATRN is the only protein found differentially abundant in the early asymptomatic stage of ADAD but 
not in the later stage. ATRN is expressed as three isoforms, with isoform 1 having a C-terminal 
extension that anchors the protein in the membrane, whereas isoforms 2 and 3 are secreted. No 
peptides specific to any of the three isoforms were detected; hence, no conclusions can be drawn on 
presence or quantity of the individual isoforms. Expression of the secreted isoforms is down-regulated 
in the human brain and these isoforms have been shown to disrupt neurite formation in vitro 39. By 
contrast, the membrane-bound isoform is expressed in the CNS, where it is critical for myelination 
39,40. Rats with loss of function mutations in glycosylated transmembrane ATRN have age-dependent 
spongiform degeneration, hypomyelination and abnormal ROS metabolism in the brain 41-43. ATRN is 
also involved in the regulation of skin pigmentation, energy control and immunity 44,45. In the immune 
system, ATRN regulatory activity allows immune cells to interact to form regulatory clusters. This 
regulatory activity of ATRN might be affected by the balance of membrane-bound and soluble 
isoforms 46. The mechanism of ATRN function is not well understood with suggestions of DP4 
protease activity for ATRN being disputed 47. 
 
Proteins in hemostasis and vascular health 
Two proteins with functions in hemostasis and vascular health were found differentially abundant in 
the NC, aMC and sMC groups. Both proteins are also able to modulate the immune response, 
reflecting the close connection of these systems. 
 
HRG modulates a variety of biological processes, including blood coagulation, fibrinolysis, 
angiogenesis, complement activation and aggregation of immune complexes 48,49. It exerts its influence 
via binding of various ligands, e.g. heparin, heparin sulphate, plasminogen and plasmin, fibrinogen, 
complement component C1q, IgG, Fc γ receptor and divalent cations 50. Similar to AHSG mentioned 
above, HRG also belongs to the cystatin type 3 family of proteins, and is able to inhibit the formation 
of spontaneous apatite calcifications formed from calcium and phosphate ions (both divalent cations) 
in vitro. Hence, it possibly prevents ectopic calcification 50. Levels of HRG in blood were reported to 
differ between MCI 5 and AD 51 subjects and healthy controls. 
 
HCII is a SERPIN that in the presence of glucosaminoglycans (e.g. heparin or dermatan sulphate) 
inhibits thrombin. HCII is particularly relevant in the intima and media of the vascular wall, which is 
rich in dermatan sulfate 52. As such, HCII protects against thrombin-induced vascular remodelling and 
consequently atherosclerosis 53. It may also promote angiogenesis via an AMP-activated protein 
kinase-endothelial nitric oxide synthase pathway 54. Hence, HCII has been suggested as a therapeutic 
target and potential biomarker for arterial disease 53-55.  
 
Proteins in lipid metabolism 
Four apolipoproteins, ApoA1, ApoA4, ApoC1 and ApoM, differed in abundance in NC, aMC and 
sMC groups. Apolipoproteins are constituents of lipoprotein particles, such as chylomicrons, VLDL, 
LDL and HDL, which transport lipids between tissues for fuel and cholesterol metabolism. The 
apolipoproteins serve as carrier, receptor-binding and regulatory proteins in these particles. As such, 
they are crucial components in lipid metabolism with implications for cardiovascular disease, obesity 
and diabetes mellitus (for a review see 56). Recently, the apolipoproteins have also emerged as a 
protein family of particular interest in AD, since alterations in lipid metabolism have been associated 
with AD pathology 57,58 and the APOE ε4 allele is the most significant genetic risk factor for LOAD. 
Furthermore, plasma levels of clusterin (also known as apolipoprotein J) are emerging as a meaningful 
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